Table 1 Evolution and change from baseline in the percentages and absolute counts of overall lymphocyte populations and CD4+T cell subsets in PBMCs.

Per-protocol predefined population, people with RRMS treated with 14 mg of teriflunomide. Peripheral blood mononuclear cells (PBMCs) isolated and analyzed by flow cytometry at baseline and 6 months. Data are represented as mean (SD) or median (IQR). Change from baseline represented as least squares means (LSM) change (SEM) or median (IQR). P values from linear mixed model analysis of month 6 with baseline. N/A, not applicable

LymphocytesCD4+ T cellsCD8+ T cellsCD19+ B cellsRatio CD4/CD8
Absolute counts
(cells/μl)
Baseline
Month 6
Δ from baseline
P value		1882.8 (651)
1587.9 (451)
−284.94 (47.3)
<0.001		1036.1 (449.7)
913.9 (383.6)
−101.14 (30.91)
0.002		154.3 (97.7; 203.9)
118.4 (67.5; 233.9)
−34.7 (−55.5;−5.3)
0.005		N/AN/A
Lymphocytes
(% PBMC)		CD4+ T cells
(% CD3+ cells)		CD8+ T cells
(% CD3+ cells)		CD19+ B cells
(% lymphocytes)		Ratio CD4/CD8
Frequencies
Baseline
Month 6
Δ from baseline
P value		79.5 (9.1)
76.7 (11.3)
−3.05 (1.43)
0.040		82.9 (74.9; 88.2)
85.3 (79.1; 91.2)
1.6 (−0.5; 3.7)
0.006		12.5 (8.9; 18.6)
10.9 (6.7; 16.9)
−1.0 (−3.5; 0.4)
0.009		10.6 (7.7; 14.9)
7.7 (6.4; 11.8)
−2.0 (−4.1; 0)
0.001		6.8 (4.2; 9.9)
7.8 (4.8; 12.8)
0.6 (−0.2; 3.9)
0.008